120 related articles for article (PubMed ID: 29618301)
1. 2,5-Diketopiperazines: A New Class of Poly(ADP-ribose)polymerase Inhibitors.
Nilov DK; Yashina KI; Gushchina IV; Zakharenko AL; Sukhanova MV; Lavrik OI; Švedas VK
Biochemistry (Mosc); 2018 Feb; 83(2):152-158. PubMed ID: 29618301
[TBL] [Abstract][Full Text] [Related]
2. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
3. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
4. Modeling of the Enzyme-Substrate Complexes of Human Poly(ADP-Ribose) Polymerase 1.
Nilov DK; Pushkarev SV; Gushchina IV; Manasaryan GA; Kirsanov KI; Švedas VK
Biochemistry (Mosc); 2020 Jan; 85(1):99-107. PubMed ID: 32079521
[TBL] [Abstract][Full Text] [Related]
5. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Cao R
J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
[TBL] [Abstract][Full Text] [Related]
6. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
7. Exploring the effect of PARP-1 flexibility in docking studies.
Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A
J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306
[TBL] [Abstract][Full Text] [Related]
8. 2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.
Gohlke BO; Overkamp T; Richter A; Richter A; Daniel PT; Gillissen B; Preissner R
BMC Bioinformatics; 2015 Sep; 16():308. PubMed ID: 26403354
[TBL] [Abstract][Full Text] [Related]
9. Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
Kumar C; P T V L; Arunachalam A
Comput Biol Chem; 2019 Jun; 80():314-323. PubMed ID: 31078910
[TBL] [Abstract][Full Text] [Related]
10. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
[TBL] [Abstract][Full Text] [Related]
11. Binding mode of novel 1-substituted quinazoline derivatives to poly(ADP-ribose) polymerase-catalytic domain, revealed by X-ray crystal structure analysis of complexes.
Matsumoto K; Kondo K; Ota T; Kawashima A; Kitamura K; Ishida T
Biochim Biophys Acta; 2006 May; 1764(5):913-9. PubMed ID: 16631419
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase.
Kinoshita T; Nakanishi I; Warizaya M; Iwashita A; Kido Y; Hattori K; Fujii T
FEBS Lett; 2004 Jan; 556(1-3):43-6. PubMed ID: 14706823
[TBL] [Abstract][Full Text] [Related]
14. The key residues of active sites on the catalytic fragment for paclitaxel interacting with poly (ADP-ribose) polymerase.
Wang Y; Bian F; Deng S; Shi Q; Ge M; Wang S; Zhang X; Xu S
J Biomol Struct Dyn; 2011 Jun; 28(6):881-93. PubMed ID: 21469749
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel PARP-1 inhibitors by structure-based virtual screening.
Hannigan K; Kulkarni SS; Bdzhola VG; Golub AG; Yarmoluk SM; Talele TT
Bioorg Med Chem Lett; 2013 Nov; 23(21):5790-4. PubMed ID: 24074844
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
Velagapudi UK; Langelier MF; Delgado-Martin C; Diolaiti ME; Bakker S; Ashworth A; Patel BA; Shao X; Pascal JM; Talele TT
J Med Chem; 2019 Jun; 62(11):5330-5357. PubMed ID: 31042381
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose)--a unique natural polymer structural features, biological role and approaches to the chemical synthesis.
Drenichev MS; Mikhailov SN
Nucleosides Nucleotides Nucleic Acids; 2015; 34(4):258-76. PubMed ID: 25774719
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine.
Nilov D; Maluchenko N; Kurgina T; Pushkarev S; Lys A; Kutuzov M; Gerasimova N; Feofanov A; Švedas V; Lavrik O; Studitsky VM
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245127
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement.
Wigle TJ; Blackwell DJ; Schenkel LB; Ren Y; Church WD; Desai HJ; Swinger KK; Santospago AG; Majer CR; Lu AZ; Niepel M; Perl NR; Vasbinder MM; Keilhack H; Kuntz KW
Cell Chem Biol; 2020 Jul; 27(7):877-887.e14. PubMed ID: 32679093
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
Goodfellow E; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
Bioorg Med Chem Lett; 2017 Feb; 27(3):688-694. PubMed ID: 28003142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
